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Case presentation
A 35-year-old woman was first evaluated at the New England
Medical Center (NEMC) at age 21 because of recurrent urinary tract
infections. She was well until age 18, when she went to a gynecologist
because of dysuria and dyspareunia. Cystitis was diagnosed and a 10-
day course of Gantrisin® was prescribed. Her urinary symptoms
improved transiently, but dysuria and urinary frequency recurred
intermittently over the next 2 years. Her only medication during this
interval was OrthoNovum® oral contraceptive tablets.
At age 20, microscopic hematuna was noted and a urine culture
revealed proteus. Cystoscopy was performed and subsiding hemorrhag-
ic cystitis was diagnosed. Antibiotics were administered for 19 days,
after which a followup urine culture was negative. An IVP demonstrat-
ed incomplete ascent and malrotation of the right kidney. The left
kidney and bladder were normal; neither ureter was dilated. Six months
later the patient again developed dysuria; urine culture revealed Esche-
richia coli, which promptly responded to treatment. Shortly thereafter,
however, coagulase-negative staphylococcus was detected in the urine
on repeated cultures. Antibiotic therapy was again prescribed and
followup urine cultures were negative. Repeat cystoscopy disclosed no
lower urinary tract pathology.
At age 21, when first evaluated at the NEMC, physical examination
was normal. Serum creatinine was 0.7 mgldl. Urinalysis revealed 1 +
protein, 3 to 5 red blood cells per high-power field, 5 to 6 white blood
cells per high-power field, and rare granular casts. A 24-hr urine
collection contained 70 mg of protein, Two urine cultures were nega-
tive. Repeat IVP was unchanged. During the next year, several urine
cultures revealed coagulase-negative staphylococcus in low colony
counts, but no symptoms were reported. Six months later, however, the
patient noted dysuna and increasing urinary frequency; at that time,
urine cultures revealed less than 1000 col/ml of mixed fecal flora.
Antibiotics were withheld. Urine cultures were obtained every 3
months over the next year and were negative on each occasion despite
minor urinary symptoms from time to time.
At age 23 she left the Boston area for 4 years, during which she
remained free of urinary symptoms. When she returned at age 27,
pyuria was noted by her private physician during a routine visit; a urine
culture was not obtained but she was treated with antibiotics. Pyuria
persisted. When reevaluated at the NEMC, she was asymptomatic, the
physical examination was normal, and a urine culture was negative for
common pathogens as well as for acid-fast bacilli. Serum creatinine was
0.7 mg/dl and 24-hr urinary protein excretion was 100 mg.
Well-documented, symptomatic urinary tract infections occurred at
ages 28, 30, and 34. On two occasions the offending organism was E.
coli; once it was klebsiella. On each occasion, the infection responded
promptly to I g of Gantrisin® four times daily, administered for 3
months, 6 months, and 10 days, respectively. Routine urine cultures,
obtained at 2 to 4 monthly intervals between symptomatic infections,
were consistently negative. A repeat IVP performed at age 31 was
unchanged. Currently, serum creatinine is 0.8 mg/dl and urinalysis is
normal.
Discussion
DR. LARS A. HANSON (Department of Clinical Immunology,
Institute of Medical Microbiology and Department of Pediat-
rics, University of GOteborg, Goteborg, Sweden): Urinary tract
infections (UT!) constitute an important medical problem for
several reasons. They are common, often recurrent, frequently
difficult to treat, and can result in parenchymal damage suffi-
cient to cause renal insufficiency. Urinary tract infections are,
in actuality, a group of diseases with widely different character-
istics; these differences arise from the variable pathogenic
capacity of the infecting bacteria and the variable efficiency of
the host's defenses. The clinical features of these infections
depend directly on the specific host-parasite relationship [1, 21.
Clinical aspects of UT!. The wide range of clinical patterns of
UT! includes acute symptomatic infection involving the kidney,
which poses a threat to the renal parenchyma and its function.
Asymptomatic bacteriuria (ABU) is at the other end of the
spectrum: Patients with covert bacteriuria have few or no
symptoms of UTI, and bacteriuria is generally discovered only
on routine examination, Obstructive changes in the urinary
tract are found in about 10% of boys and 2% of girls examined at
the time they develop their first symptomatic UTI [3]. In these
patients, surgical procedures or other measures are required to
prevent renal parenchymal damage; the same holds true for
patients with neurogenic dysfunction. I will direct my com-
ments toward the problem of nonobstructive UT! in the pediat-
ric age group.
Presentation of the Forum is made possible by grants from Smith
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Approximately 1% of girls are found to have asymptomatic
bacteriuria during school screening programs. Three percent of
all girls develop symptomatic UT! before the age of 10. Where-
as symptomatic UT! is as common in boys as it is in girls during
the first year of life, a female predominance is evident thereafter
[3]. Approximately 30% of girls with UT! have a recurrence
within a few months after their first symptomatic infection, and
almost 60% of those who have one recurrence have another. It
is striking that the frequency of symptoms decreases with each
recurrence [31: "asymptomatic" recurrences occur in one-third
of patients with initial symptomatic UTI and in three-fourths of
patients with a previous asymptomatic infection [4].
Renal scarring develops in about 5% of girls and 13% of boys
monitored after their first symptomatic UTI [3]. When the
initial infection is acute pyelonephritis, the risk of the child
developing renal parenchymal scarring is about 10%; this risk
increases with the number of febrile attacks [5]. Renal scarring
and impairment of renal growth are common; 10 to 15 years
after a bout of acute pyelonephritis, glomerular filtration rate is
generally normal or almost normal, but this preservation of
function commonly results from compensatory hypertrophy of
the contralateral undamaged kidney [4, 61. Patients with bilater-
al scarring probably have a higher risk of progressive deteriora-
tion of renal function than do those with unilateral scarring.
Despite the fact that refiux occurs less commonly after the age
of one year in children with symptomatic infection, recurrences
of infection are just as common after one year of age as before
[31. Refiux often vanishes spontaneously; perhaps this is why
the risk of later infection is not increased in those who have had
reflux early in life. On the other hand, renal mass at followup
examination is significantly decreased in kidneys of patients
who had grade 2 or 3 reflux at the time of their first UTI
compared to patients who had no reflux or only grade 1 refiux.
Compensatory hypertrophy of the contralateral kidney does not
appear to be affected by the presence of vesicoureteral reflux
[6]. Patients with severe refiux with dilatation and UTI have a
high risk of developing renal damage, but such patients are rare.
Renal scarring is not related to the presence of low-grade
vesicoureteral reflux and sometimes occurs in the absence of
reflux.
Some evidence indicates that effective early treatment might
be important in the prevention of renal scarring [6]. Renal
scarring has been found in 20% to 25% of school girls with ABU
discovered by routine screening [7]. In our studies, we detected
renal scarring in only 10%, possibly because of the active
treatment and followup program for this patient group that was
initiated in our area in the early 1960s [4, 8]. The cause of the
renal damage found in our studies is unknown, but it might be
related to undiagnosed attacks of pyelonephritis early in life. It
is interesting that in a group of 14 untreated girls with ABU but
no refiux or renal scarring at the onset, the kidneys grew
normally, and no signs of scarring were evident after 3 years of
followup [9].
At present we know little about why some patients have only
a single infection and others have recurrences, or why some
develop renal scarring and impaired kidney growth. It would be
useful if we could predict at an early stage which course an
individual patient would be likely to follow. If we could identify
such patients prospectively, we could avoid initiating extensive
radiologic and laboratory investigations and long-term treat-
ment in the group at low risk of renal damage. On the other
hand, it would be of considerable value if we could identify
patients at high risk of developing repeated infections and renal
damage, because such patients might benefit from detailed
investigations and long-term treatment. Toward this end we
attempted to assess whether the renal parenchyma was in-
volved when urinary infection was present; we assumed that
patients with evidence of renal parenchymal involvement are at
greater risk of developing renal scarring subsequently.
Methods of assessing parenchymal involvement. The ques-
tion is how to determine reliably whether the renal parenchyma
is affected by infection. Ureteric catheterization would allow us
to determine whether bacteria are present in the upper reaches
of the urinary tract, but it clearly is inappropriate to carry out
such studies in a large group of children with symptomatic and
asymptomatic UT!. For this reason, we have explored the use
of a variety of tests as predictors of the presence or absence of
parenchymal infection. First, we noted that in patients pre-
sumed on clinical grounds to be suffering from acute pyelone-
phritis, the presence of fever correlated well with increased
serum levels of C-reactive protein (CRP) and with lowered renal
concentrating capacity [10]. The sedimentation rate was usually
elevated, but the increase appeared later than the increase in
the CRP and did not return to normal as fast as the CRP. In fact,
the changes in CRP paralleled the clinical course so well that we
found it useful in monitoring treatment [11]. During successful
treatment of bactenurta, the CRP returned to normal within a
few days after the onset of infection. With failure of therapy or
recurrence, the CRP remained high or increased again, respec-
tively. Although the CRP is nonspecific, that is, it could be
correlated merely with fever, we believe that a CRP determina-
tion might be the simplest, most inexpensive way to determine
the presence or absence of parenchymal involvement [10—12].
There was also generally an increased level of antibodies in the
serum against the 0 antigen of the infecting bacteria in patients
with clinical findings consistent with acute pyelonephritis, but
not in those with findings consistent with acute cystitis [10, 13,
14].
We assessed whether the bladder washout test correlated
with the CRP, the presence of fever, or the alteration in renal
concentrating capacity, but we found that the correlation was
poor; this result might be explained by an intermittent discharge
of bacteria into the renal pelvis [101 or by the presence of reflux.
It should be pointed out that none of the methods that we tested
identified precisely the site or sites of infection in patients with
ABU [15].
The test for antibody-coated bacteria has been proposed for
use in distinguishing between cystitis and pyelonephritis [16,
17]. A number of reports have indicated, however, that this test
is not very sensitive in children [18, 19] and, in fact, its efficacy
also has been questioned in adults [20]. Finally, determination
of urinary lactic dehydrogenase isoenzyme 5 and f32-microglob-
ulin may be useful for assessing the presence or absence of
renal involvement [21, 22].
Let me summarize the available data. The typical findings in
acute symptomatic pyelonephritis in children include a tem-
perature above 38.5° C, a CRP greater than 20 mg/liter, a
microsedimentation rate greater than 25 mm/hr, and lowered
renal concentrating capacity during the acute stage of infection.
The patient with acute cystitis typically has dysuria and fre-
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quency, a temperature not exceeding 38° C, no back or loin
pain, and normsl values for CRP and sedimentation rate.
We recently have found another useful method of assessing
the presence of renal involvement. In patients with acute
pyelonephritis who have no evidence of renal scarring, both
IgG and IgA antibodies against the Tamm-Horsfall protein are
increased [23, 24]. In contrast, neither IgG nor IgA antibodies
to this protein are increased in patients thought to have acute
cystitis or in those with ABU. Further studies revealed that
among patients with clinical findings of acute pyelonephritis,
antibody titers were significantly higher in those with reflux
than in those without reflux. Furthermore, IgG anti-Tamm-
Horsfall antibodies were normal or only slightly increased in
patients who had acute pyelonephritis and renal scarring. The
titers were especially low in patients with renal scarring and
increased serum creatinine. In fact, an inverse relationship
existed between serum creatinine and IgG anti-Tamm-Horsfall
antibody titers; the lowest level of these autoantibodies was
found in patients who had the highest serum creatinine levels
[25, 26]. These observations suggest that Tamm-Horsfall IgG
antibody determination might be a useful adjunct in assessing
whether the renal parenchyma is involved in patients with UTI.
Antibodies to the Tamm-Horsfall protein, which are present
in everyone, increase with age; appreciable levels are found by
the age of 8 months [24]. This observation, taken together with
the increased levels of antibodies to the Tamm-Horsfall protein
induced by infections with various E. coil and proteus species
[27], suggested the presence of a cross-reaction between the
Tamm-Horsfall protein and a common structure on gram-
negative organisms. Evidence for such a cross-reaction was
found [28], although it is not known at present whether the
cross-reaction explains the appearance of the Tamm-Horsfall
antibodies.
Although detection of high titers of antibodies against the 0
antigens of infecting E. co/i might be useful in identifying renal
parenchymal involvement [10, 13, 14], the large number of
different 0 antigens on the infecting bacteria makes the test
laborious. Using a pool of the most common 0 antigens
simplifies the procedure to some extent, but this approach
yields a less sensitive test [29, 30]. In a search for antigens
common to E. coil, we studied the antibody response against
lipid A, the toxic portion common to endotoxins. Such antibod-
ies did not differentiate among symptomatic pyelonephritis,
symptomatic cystitis, and ABU [31]. We found, however, that
patients with recent renal parenchymal contraction had the
highest titers against lipid A [31]. Because of the small number
of patients with signs of progressive renal scarring, the experi-
ence is yet too limited for us to say whether measurements of
anti-lipid A can become a useful test for identifying a subgroup
of patients whose risk of parenchymal loss is particularly high.
Characteristics of E. coli and proteus causing UTI. As with
most infections, the virulence of the infecting microorganism
influences, and can even determine, the course and outcome of
UTI. We have looked for factors that determine the virulence of
E. coil and proteus strains, two of the most common species
causing UTI in children and adults. We found that 80% of theE.
coil causing acute pyelonephritis carried endotoxins or lipo-
polysaccharides belonging to only eight different 0 antigen
groups, whereas only 2% of the cases were caused by bacteria
that were spontaneously agglutinating, that is, which had in-
complete 0 antigens or endotoxins (Table 1). By contrast, only
31% of the children with ABU had bacteria with the eight most
common 0 groups, and 45% had spontaneously agglutinating
strains. These apparently low virulence strains were, nonethe-
less, more common in the urine of the ABU patients than they
were in the stool of healthy school children [2, 15, 32—34]. This
finding suggests that a selection mechanism might be making
some strains of E. coil more efficient in reaching the urinary
tract and causing infection.
The acidic polysaccharide capsule may be another virulence
factor. We found that approximately 70% of strains causing
acute pyelonephritis in children belonged to only five different
K antigen types [35]. Among these five, the Kl capsule was
found in 39% of the strains causing acute pyelonephritis. This is
the same capsular antigen found on approximately 80% of E.
coil strains that cause neonatal meningitis [36].
To assess the virulence of E. coil strains, one can test the
sensitivity of E. coil to the bactericidal activity of normal
serum. Strains causing either pyelonephritis or cystitis were the
most resistant, whereas strains in the urine of patients with
ABU were the most sensitive (Table 2) [32, 33, 37]. Again, this
finding indicates that the strains in patients with ABU are less
virulent than are those in patients with symptomatic infections.
We noted that the stool strains from healthy school children
were less sensitive to the bactericidal activity of normal serum
than were the urinary isolates from the ABU patients; this
finding suggests to us that the strains carried unnoticed for
months in the urinary tract of the patients with ABU may
acquire a different form than they possessed in the stool. This
suggestion is supported by the observation that patients with
asymptomatic recurrences appearing shortly after discontinua-
tion of antibiotic therapy tend to be infected with organisms
closely similar to those in their stool [33].
During our search for virulence factors of E. coil, we noted
that strains from patients with clinical evidence of acute pyelo-
nephritis usually attached efficiently to human urinary tract
epithelial cells, whereas strains from patients with ABU at-
tached poorly or not at all (Fig. 1, Table 3) [38—40]. Svanborg
Eden et a! have suggested that E. co/i need to attach to mucosal
epithelium to initiate UTI [40]. The variable capacity of certain
strains of E. coii to attach to the urinary tract in humans might
be one explanation for the various clinical expressions of UTI:
it is possible that only bacteria capable of attaching efficiently
can come into sufficient contact with the host to cause symp-
tomatic cystitis and pyelonephritis, whereas bacteria that are
unable to attach, or attach poorly, produce only ABU. I should
point out, however, that this hypothesis is not consistent with
all the findings: approximately 30% of the strains causing acute
pyelonephritis did not attach to epithelial cells in vitro, and
approximately 30% of the strains from patients with ABU did
attach to the uroepithelium [39]. The explanation for the lack of
adherence of those organisms that were apparently pathogenic
is uncertain. It is possible that these bacteria were not cultured
in an optimal way or that the in vitro method was not optimal
for detecting various attachment mechanisms. Alternatively,
perhaps antibodies in the urine of these patients prevent attach-
ment and symptoms.
The capacity of bacteria to attach to uroepithelial cells
correlates with the presence of bacterial fimbriae or pili [41].
These pili seem to mediate attachment and bind to specific
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Table 1. Distribution of 0 antigen groupsa
Clinical Clinical Asymptomatic
pyelonephritis cystitis bacteriuria
Normal
stool flora
Eight most common 0 groups" 80% 59% 31%
Other 0 groups 18% 35% 24%
Spontaneously agglutinating 2% 6% 45%
28%
50%
22%
Number of strains 119 109 115 711
Data compiled from work of Lindberg and Lidin-Janson et al.
b 01, 02, 04, 06, 07, 016, 018, 075.
Table 2. Mean sensitivity to the bactericidal effect of normal seruma
Clinical Clinical Asymptomatic
pyelonephritis cystitis bacteriuria
Normal
stool flora
Eight most common 0 groups" 0.5' 0.3 1.8
Other 0 groups 0.4 0.6 2.5
Spontaneously agglutinating 0.5 1.5 2.6
1.0
0.8
2.2
Number of strains 119 109 115 711
Data compiled from work of Oiling et al [371.
b 01, 02, 04, 06, 07, 016, 018, 075.
Sensitivity grading: 0, most resistant; 3, most sensitive.
receptors on the uroepithelium. The receptors consist of glyco-
lipids belonging to the globo series [42—44j. E. co/i also carry
type-i pili, which bind to mannose-containing residues and to
urinary slime [45]. The type-l pili do not bind to human urinary
epithelium; instead these pili bind to mucus, thus possibly
helping to eliminate bacteria from the urinary tract [45}. Recent
data suggest that the urinary slime to which type-I pili bind at
least partly might consist of Tamm-Horsfall protein ([46], Fasth
A, Hanson LA, Svanborg Eden C, unpublished data).
It is possible that recurrent infection in some patients might
result because their urinary tract epithelial cells and periureth-
ral cells bind more bacteria than do normal cells [47—50]. The
basis for this binding is not known but might relate to the form
or function of the glycolipid receptors for the bacterial pili.
Proteus, the second most common pathogen of urinary tract
infection, rarely causes acute pyelonephritis in children [27]. It
ordinarily causes UTI only in the presence of obstruction or
stones. Proteus might be less virulent because proteus strains
lack the capsules that E. co/i have. Further, E. coli can attach to
squamous as well as transitional epithelium from the urinary
tract, but proteus attaches only to squamous epithelium (Table
3) [51]. This low capacity to adhere to the urinary bladder might
allow the bacteria to be washed out with the urine before an
infection can be established.
Antibody response in UTI. Urinary tract infections induce an
antibody response in the serum as well as in the urine [13, 14,
29, 30, 52]. The serum antibody response in UTI is composed of
1gM, IgG, and IgA antibodies. Serum antibodies against the 0
antigen of the infecting strain increase in most cases of acute
pyelonephritis but not in acute cystitis or ABU [13, 14, 29, 30].
In contrast, antibodies to the K antigen of the infecting strain
are less often produced even in acute pyelonephritis, possibly
because these poiysaccharide antigens can induce tolerance
[53]. Antibodies against type-i pili [54j as well as against lipid A
[31] also increase during UTI.
The urinary antibody response during acute UTI is limited to
production of IgG and secretory IgA [52]. Secretory IgA
antibodies are produced either locally after direct antigenic
exposure of a mucous membrane, or after antigenic stimulation
of the Peyer's patches in the intestine. Antigen-primed lym-
phoid cells leave the patches and seem to migrate to various
sites of secretory IgA production such as the intestinal mucosa
and the salivary and mammary glands. Because secretory IgA
antibodies appear in the urine in UTI, it may be that the urinary
tract is part of the integrated mucosal defense system provided
by secretory IgA [55].
The urinary antibodies are directed against E. co/i 0 antigens
and probably also against the bacterial pili [40, 52, 54]. Secre-
tory IgA antibodies appear within the first week after the onset
of infection. This rather rapid IgA response may signify that the
urinary antibodies are part of a secondary response. The
primary response might have occurred in the intestine after
exposure to the same bacterial strain, which later found its way
into the urinary tract and caused the UTI. The supposed
priming in the intestine could result in committed IgA-produc-
ing cells that migrate from Peyer's patches to the urinary tract
[55]. The assumption that the urinary tract may be part of the
secretory IgA mucosal defense system is supported by rat
experiments. Ascending pyelonephritis in the rat results in the
appearance of IgA antibodies against the infecting strain in milk
as well as in bronchial secretions, although no such antibodies
are found in the serum (Mattsby-Baltzer I, Hanson LA, Kaijser
B, Olling S, unpublished observations). The site of production
of urinary IgA is not known, but in patients undergoing
nephrectomy before renal transplantation, Hong et al noted that
washout fluid from the bladder contains secretory IgA [56].
Studies of renal tissue from nephrectomized patients and rab-
bits with experimental pyelonephritis did not demonstrate any
substantial IgA production in the kidney, but there was evi-
dence of IgG synthesis [57, 58].
Whether the antibodies produced against the infecting bacte-
ria in patients with acute pyelonephritis protect against UT! is
Fig. 1. Scanning electron microscopy of E.
coli bacteria attaching to human urinary tract
epithelial cells. Photo by C. Svanborg Eden
[39, 40].
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Table 3. Attachment of various bacteria to human urinary tract epitheliuma
Attachment
Species Clinical diagnosis Origin
No. of
strains
(bacteria/epithelial cells)
Transitional Squamous
Escherichia coli Acute pyelonephritis
Acute cystitis
Asymptomatic bacteriuria
Urine
Urine
Urine
30
30
30
16
8
2
17
8
5
Proteus mirabilis Urinary tract infection
Adults
Children
Bacteremia
Diarrhea
Healthy
Urine
Urine
Blood
Stool
Stool
30
30
30
30
30
0
0
0
0
0
17
25
19
18
26
a Compiled from work of Svanborg Eden et al.
uncertain, but they seem to be protective in experimental
disease. In experimental animals, serum IgG and 1gM antibod-
ies against 0 antigen as well as K antigens of E. co/i protected
against E. co/i infections [59, 60]. Local immunization in the
urinary bladder of formalin-killed E. co/i also protected against
ascending acute pyelonephritis in rats. This protection could be
transferred with the urine from immunized to nonimmunized
animals [61]. Furthermore, immunity against ascending pyelo-
nephritis in the rat can be produced by prior intestinal coloniza-
tion with the same strain of bacteria (Mattsby-Baltzer I, Hanson
LA, Kaijser B, Oiling S, unpublished observations). It is not yet
clear whether this protection is mediated by serum antibodies,
by the secretory IgA system, or by both. The poorly immuno-
genic K 13 antigen of E. co/i can be made into an efficient
immunogen by coupling it to a protein carrier. The resulting
K13 protein conjugate protects against ascending pyeionephri-
tis in rats and against peritonitis caused by a K13 strain of E.
coli in mice [62]. Immunization of rats with E. co/i pili (type 1)
also protected against ascending pyelonephritis [63].
Treatment of patients with UTI on the basis of the host-
parasite relationship. We believe that acute pyelonephritis and
frequent febriie recurrences increase the risk of renal scarring
and of impaired growth of the kidneys; therefore, we think that
such infections must be diagnosed early and treated vigorously.
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But patients with ABU caused by bacteria of low virulence
usually do well without treatment [91; approximately 10% of
untreated patients with ABU lose their bacteriuria spontane-
ously each year. When patients with ABU are treated, about
50% experience one recurrence and about 20% have repeated
recurrences [4, 64]. After 5 years, equal numbers of treated and
untreated patients have persistent bacteriuria. We have hypoth-
esized that bacteria tend to lose virulence factors in the process
of adapting to specific antibodies directed against them, includ-
ing the urinary antibodies [2]. A significant loss of virulence of
E. coli occurs after 5 months in the urinary tract of rats with
long-term bacteriuria (Mattsby-Baltzer I, Hanson LA, Kaijser
B, Larsson P, Oiling S, Svanborg Eden C, unpublished obser-
vations). Losing virulence, the bacteria become harmless and
are eliminated ultimately by urinary washout.
Treatment of ABU in children may have adverse conse-
quences [64]. Since the bacteria that cause recurrences origi-
nate in the stool, they can possess a number of virulence factors
(e.g., common endotoxins, K antigens) and a high capacity to
attach to urinary tract epithelium. The result of treatment
ironically can be an attack of acute pyelonephritis instead of the
harmless ABU [65]. Because of this possibility, we must
develop better ways of determining when to treat patients who
have ABU. The capacity of bacteria to attach to uroepithelium
in a patient with bacteriuria might be a useful parameter for
determining whether treatment is needed. A normal CRP level
might provide another useful parameter; if no inflammatory
process exists in the renal tissue, there may be no urgent reason
for treatment. Because the CRP is a nonspecific parameter,
however, other inflammatory processes must be excluded when
the test is positive.
It is critically important that we identify early the group at
high risk of developing renal scarring. As I already mentioned,
increased levels of IgG antibodies to the Tamm-Horsfall protein
during acute pyelonephritis should raise the possibility that the
patient has reflux. The significantly lower levels of IgG antibod-
ies to Tamm-Horsfall protein in noninfected periods in patients
with renal scarring may point the way to a less risky and less
expensive means than radiologic studies to detect these high-
risk patients. In patients with scarring who have been followed
for 10 to 15 years after their first known infection, we noted
long-lasting renal growth impairment. In those with an undam-
aged contralateral kidney, compensatory hypertrophy occurred
[4, 6]. These girls had been closely monitored, and recurrences
had been treated. Obviously, more active measures are re-
quired, such as longer periods of treatment, or the still hypo-
thetical possibility of prophylactic vaccination. No such vac-
cine yet exists for human use, but immunization of rats and
rabbits prevents pyelonephritis [59, 61, 63]. The most common
E. co/i capsular K antigens [35] coupled to a protein carrier [62]
could be candidates for a vaccine for human use. E.co/i pili also
might be a useful vaccine component, possibly in combination
with the K antigens. Such a vaccine could be tried in the
different "risk" groups, as defined by means of determinations
of CRP and IgG anti-Tamm-Horsfall protein. Because renal
scarring appears during the first years of life, early vaccination
might prevent recurrent pyelonephritis and thus obviate renal
parenchymal scarring.
Questions and answers
DR. JEROME P. KASSIRER: Dr. Hanson, it is not clear to me
from your discussion what you consider the diagnostic "stan-
dard" that confirms the presence of pyelonephritis. Did you use
contraction of renal mass as unequivocal evidence of previous
kidney infection?
DR. HANSON: I do not believe that progressive reduction of
renal mass can be the only criterion. Progressive reduction
seems to occur also in the absence of acute infection. As you
know, French scientists claim that what is called renal scarring
cannot always be safely distinguished from congenital changes.
Also, since only a minority of patients with renal infections
develop parenchymal reduction, you would end up with a rather
small group. Because there are no methods readily available
that demonstrate actual infection in the kidney, e.g., biopsy or
catheterization, we have to accept second-best methods. We
carefully define our clinical criteria for diagnosis and, using
these criteria as a basis, we compare all possible diagnostic
studies. We have used the same diagnostic criteria for 20 years
and are confident that urinary tract infections in fact involve the
kidney if one finds a decrease in the concentrating capacity,
increases in CRP and sedimentation rate, and increases in
antibodies against the infecting bacteria and against the autoan-
tigen Tamm-Horsfall protein. I think it would be difficult to
press the issue further at present. Acute pyelonephritis as a
diagnosis in a scientific study is, in my mind, not a certain
diagnosis but rather one with a high probability. If you define
your criteria as we have done, useful information can be
obtained. We are running three new prospective studies that
might add to our information on this point.
DR. JORDAN J. COHEN: If we accept your thesis that host
factors are critically important in the group at high risk for
recurrent infection, what do you envision as the mechanism
whereby long-term treatment could alter the pattern of recur-
rences in such a group?
DR. HANSON: Let me start with a very general statement. On
one hand, I claim that the immune defense is important. On the
other hand, in my experience there is no higher frequency of
urinary tract infections in patients with hypogammaglobulin-
emia. I claim that IgA is a very important defense factor; one-
half of our lymphoid system produces IgA and one-half of all
antibodies are IgA. Yet I have looked for IgA deficiency in our
patients and it's not common. I think these apparent discrepan-
cies illustrate a point; the host defense system in the urinary
tract is very complicated. If one element fails, several others
take over. In my mind, the main host defense factor in the
urinary tract is urine flow, the washout effect. Only if there is an
impairment of the washout effect do you need other defense
factors like the immune defense. When we look at the recur-
rences in our patients, 80% are with a strain with a different
serotype; this suggests to me that these patients are immune
against the previous strains.
DR. COHEN: That still does not explain the improvement that
occurs in some patients when treatment is continued for a year
or more. What happens during that year that reduces the
frequency of subsequent infection in some individuals?
DR. HANSON: Most of the recurrences occur during the first
few months after the first episode of UTI. Followup of girls with
renal scarring showed more infections in the 0- to 4-year-olds,
with two-thirds having pyelonephritis. The 5- to 9-year-olds had
fewer infections, one-half having pyelonephritis. Among the 10-
to 14-year-olds, less than one-half as many infections occurred,
most of which were ABU. When sexual activity started,
recurrences doubled, and two-thirds were ABU. Since we
know that scarring is directly related to pyelonephritis attacks
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within the first 5-year period, maybe that is the length of time
we should treat. I must admit, however, that I have not directly
answered your question and I'm not sure why prolonged
treatment is effective in some patients.
DR. KASSIRER: Suppose we divide patients with urinary
infections into two groups on clinical grounds alone, one with
evidence of upper urinary tract infection such as fever, flank
tenderness, and white cell casts, and the other with asympto-
matic bacteriuria or only local symptoms of "cystitis." If we
treated the first group with a long course of antibiotics and the
second group only with a short course, how often would we
make serious errors with regard to preventing renal damage?
DR. HANSON: I suspect that, for the most part, this approach
would greatly reduce the frequency of renal scarring, but I have
little evidence for this assertion.
DR. JEFFREY A. GELFAND (Divisions of Experimental Medi-
cine and Infectious Disease, NEMC): What is your position on
the utility and accuracy of the antibody-coated bacteria test?
How predictive do you think that test is?
DR. HANSON: The antibody-coated bacteria test is not very
effective in the pediatric age group. But I am intrigued by the
finding that the appearance of antibody-coated bacteria may
relate to the outcome of treatment in adults. It doesn't surprise
me that the test is not an accurate prediction of the site of
infection because, as I have already mentioned, patients with
asymptomatic bacteriuria have a lot of antibody in their urine.
So why wouldn't they have antibody-coated bacteria?
DR. GELFAND: Have you correlated any of the screening
tests, such as CRP, with the anatomic techniques, such as
bladder washout?
DR. HANSON: Yes. Again, the problem is that there is no
absolute standard that confirms the presence of pyelonephritis.
What we have done, therefore, is put many tests together and
try to relate one to another. We thought that the bladder
washout test would be an ideal test, but in our hands it was not.
We missed several cases of obvious renal infection, probably
because of the intermittent release of bacteria.
DR. JOHN T. HARRINGTON: Could you tell us what is the
biologic significance of the receptor for E. coli in the urinary
tract?
DR. HANSON: I don't know the answer to that but I could
suggest, for instance, that it's there for a totally different
purpose and that E. coli simply found this to be a good way to
"hook on."
DR. EDWIN M. MEARES (Chairman, Division of Urology,
NEMC): I am interested in your observation that organisms do
not attach to transitional cell epithelium. I believe that investi-
gators have shown that the instillation of proteus organisms
directly into the bladder in an animal model was soon followed
by acute pyelonephritis in most instances [661. If proteus
organisms do not attach to bladder epithelium, the high inci-
dence of acute pyelonephritis in these experiments seems
puzzling.
DR. HANSON: I would make two points. First, several ani-
mals have spontaneous reflux; that certainly could make a
difference. The second point, which might be more important,
is that attachment is not only organ specific but also species
specific. We just now are trying to develop a mouse model
instead of the rat model because we feel that the attachment
mechanisms in mice and humans are similar.
DR. MEARES: Some view the motility characteristic of pro-
teus organisms as a possible explanation for the predilection of
these pathogens to infect the kidneys. One of the most serious
complications of proteus UTI that we see in adult urologic
practice, especially in women, is staghorn renal calculi com-
posed of struvite.
DR. EDWARD A. KASS (Director, Channing Laboratory,
Brigham and Women's Hospital, Boston, Mass.): There is
another hypothesis that might help explain why proteus is such
a difficult pathogen. Rats have a relatively low level of C4
(fourth component of complement) compared to other species.
Beeson and Rowley were able to show that by inducing acidosis
they could make rats more susceptible to pyelonephritis [671.
They also showed that the medulla was anticomplementary,
and the anticomplementary effect was explained by the induc-
tion of inhibition of complement by ammonia. Since proteus
produces so much ammonia, it should inactivate C4 and inter-
fere with opsonization and bactericidal effects of antibody.
DR. SHELDON M. WOLFF (Chairman, Department of Medi-
cine, NEMC): The possibility of immunizing individuals with
the coliform antigens you discussed is fascinating but might
prove difficult. The human has existing levels of antibodies to 0
antigens and, when immunized with these antigens, the re-
sponse generally is not long-lived. I am interested in the
observation that attachment seems to vary with the day of the
menstrual cycle in women. Have you studied the effect of
various hormones such as estrogen or progesterone on attach-
ment?
DR. HANSON: We have decided to exclude the use of 0
antigens in immunizing humans although we know that they
immunize animals. There could be side effects, but that is not
the major reason. Some years ago we found that cross reactions
are common between endotoxins and renal tissue. The 020
consistently cross-reacted between tissue; 02 does also and
014 does occasionally. We presently are concentrating on the
capsular antigens that are not yet well defined. We need to
define the chemical structure of each of the antigens before
using them in humans. This unfortunately is much more compli-
cated than we had hoped. TheK2 has been confused with K62
for years, whereas the KI exists in two variants, K! plus and
KI minus. We don't know which one to use.
The pili situation is even more complicated. At present we
think we may be able to use type-I pili as immunogens. They do
vary heterogenically but they cross-react extensively and I
think it is possible. I would prefer pili that specifically bind to
the receptors I discussed. As far as your question regarding
hormones is concerned, that certainly is something of great
interest.
DR. DAVID SNYDMAN (Infectious Disease Service, NEMC):
Have you looked at passive immunization in any of your animal
models?
DR. HANSON: In the rabbit model it is easy to protect with
anticapsular antibodies. In the rat, we also can transfer protec-
tion with serum, IgG antibodies, and 1gM antibodies against K
and 0. The K antibodies protect better. In the rat, we have
immunized via the bladder with killed bacteria. We can protect
not only the animal immunized, but we also can transfer that
immunity with urine to the bladder of other rats; this observa-
tion supports a local protective immune response. I believe that
we may not have taken advantage of the fact or even noticed
that when we produce vaccines against common organisms, we
may boost immunity at the mucosal level as well as in serum.
That may be the most useful type of immunity for prevention of
recurrent UTI in children.
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Note added in proof
In some patients, bacterial adhesion in the urinary tract may have a
genetic basis. The globo series glycolipids, which act as receptors for
the majority of pyelonephritogenic E. coli, are antigens in the P blood
group system. They also are the dominating non-acid glycolipids in
kidney tissue. Persons of blood group P1 phenotype have a higher
density of compounds with receptor function in their erythrocyte
membranes (and possibly on their uroepithelial and kidney cells) than
do individuals of phenotype P2. This may explain the overrepresenta-
tion of blood group P1 phenotype in patients with recurrent pyelone-
phritis [681 and the rarity of individuals of phenotype P2. When bacterial
ascent into the kidney is facilitated by mechanical factors, e.g.,
vesicoureteric refiux of grade II or more, bacterial adhesion seems of
less importance for the pathogenesis of pyelonephritis [691. Only about
7% of pyelonephritogenic E. coil from patients with recurrent pyelone-
phritis and refiux bind to globo series glycolipids, compared to about
70% of the strains from such patients without reflux (Lomberg H,
Hanson LA, Jodal U, Leffier H, Svanborg Eden C, personal
observations).
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